Skip to main content
. 2016 May 3;6:25369. doi: 10.1038/srep25369

Figure 2.

Figure 2

The comparison of PFS (A) and OS (B) in IHCC patients with RAMlow -expressed tumors (n = 62), receiving treatment of C-GEMOX or GEMOX. (C) cetuximab; GEMOX, gemcitabine and oxaliplatin; PFS, progression-free survival; OS, overall survival; IHCC, intrahepatic cholangiocarcinoma; RAM, ROS1/ALK/c-MET.